ReviewIntestinal research2019
Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia.
Review in Intestinal research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it, 106 citations in OpenAlex.
- Asian Pacific Association of Gastroenterology (APAGE) Clinical Practice Guidelines on the Use of Small Molecules and IL-23 p19 Inhibitors in Ulcerative Colitis and Crohn's Disease.Journal of gastroenterology and hepatology · 2026Guideline
- Efficacy, Safety, and Pharmacokinetics of Upadacitinib Among Patients in East Asia With Moderately to Severely Active Ulcerative Colitis: A Post Hoc Subanalysis of Randomized Phase 3 Studies.Journal of gastroenterology and hepatology · 2026Trial
- Efficacy and safety of upadacitinib for Crohn's disease in patients in East Asia: a post hoc analysis of randomized phase 3 studies.Journal of gastroenterology · 2026Article
- Five-Year Outcomes and Disease Trajectories in Moderate-to-Severe Ulcerative Colitis: A Korean Multicenter Inception Cohort.Journal of gastroenterology and hepatology · 2026Article
- Real-World Patterns of Immunomodulator Use in Patients with Inflammatory Bowel Disease Receiving Biologic Therapy Under a 54-Week Reimbursement Cap: A 12-Year Retrospective Single-Center Cohort from Taiwan.Journal of inflammation research · 2026Article
- Advanced phenotypes and favorable 1-year outcomes with accelerated step-up strategy in newly diagnosed inflammatory bowel disease in a tuberculosis-endemic, resource-constrained setting.Therapeutic advances in gastroenterology · 2026Article
- Arrhythmogenic Implications of Inflammatory Bowel Disease: Its Mechanisms and Treatment Effects.Cureus · 2025Review
- Evolution of inflammatory bowel disease in Korea: a 60-year perspective on clinical and research development.Intestinal research · 2025Review
- Persistence of advanced therapies in patients with inflammatory bowel disease: retrospective cohort study using a large healthcare claims database in Japan.Intestinal research · 2025Article
- Influence of preoperative anti TNF alpha antibody therapy on postoperative recurrence of Crohn's disease.Scientific reports · 2025Article
- Role of 5-aminosalicylic acid in ulcerative colitis management in 8 Asian territories: a physician survey.Intestinal research · 2025Article
- Collagen Peptides andFood science & nutrition · 2025Article
- Biologics in the management of pediatric inflammatory bowel disease: When and what to choose.World journal of clinical pediatrics · 2025Review
- Mapping the Evolution of IBD Treatment: A Bibliometric Study on Biologics and Small Molecules.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Comparison of 1-Year Clinical Course in Patients With Newly Diagnosed Inflammatory Bowel Disease Between Vietnam and Korea: A Multinational, Multicenter Retrospective Cohort Study.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- Emerging Patterns of Inflammatory Bowel Disease in Sub-Saharan Africa: 175 Cases From an Inflammatory Bowel Disease Network.Journal of Crohn's & colitis · 2025Article
- Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition.Intestinal research · 2025Review
- Risk Factors ofGut and liver · 2024Article
- Therapeutic Drug Monitoring in Patients with Systemic Lupus Erythematosus: Utility and Gaps.Journal of clinical medicine · 2024Review
- Modified Gegen Qinlian Decoction modulated the gut microbiome and bile acid metabolism and restored the function of goblet cells in a mouse model of ulcerative colitis.Frontiers in immunology · 2024Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 20 institutions in 14 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Asia-Pacific Working Group on inflammatory bowel disease (IBD) was established in Cebu, Philippines, under the auspices of the Asian Pacific Association of Gastroenterology with the goal of improving IBD care in Asia. This consensus is carried out in collaboration with Asian Organization for Crohn's and Colitis. With biologic agents and biosimilars becoming more established, it is necessary to conduct a review on existing literature and establish a consensus on when and how to introduce biologic agents and biosimilars in the conjunction with conventional treatments for ulcerative colitis (UC) and Crohn's disease (CD) in Asia. These statements also address how pharmacogenetics influence the treatments of UC and CD and provide guidance on response monitoring and strategies to restore loss of response. Finally, the review includes statements on how to manage treatment alongside possible hepatitis B and tuberculosis infections, both common in Asia. These statements have been prepared and voted upon by members of IBD workgroup employing the modified Delphi process. These statements do not intend to be all-encompassing and future revisions are likely as new data continue to emerge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.